J&J un­corks new Trem­fya da­ta in ul­cer­a­tive col­i­tis as its ri­val awaits an FDA de­ci­sion

While J&J’s Janssen pre­vi­ous­ly re­port­ed that rough­ly 60% of mod­er­ate to se­vere ul­cer­a­tive col­i­tis pa­tients re­spond­ed to an IV for­mu­la­tion of Trem­fya, the com­pa­ny’s now sug­gest­ing that a fol­low-on sub­cu­ta­neous dose was able to boost re­sponse.

Just over half of pa­tients who re­ceived a 200 mg SC dose of Trem­fya af­ter not ini­tial­ly re­spond­ing to the IV ver­sion even­tu­al­ly showed a re­sponse, Janssen an­nounced on Mon­day. Pa­tients re­ceived the SC dose af­ter re­ceiv­ing ei­ther 200 mg or 400 mg of IV Trem­fya.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER